VA
VR Adviser Portfolio holdings
AUM
$1.33B
This Quarter Return
+19.93%
1 Year Return
+6.92%
3 Year Return
+862.77%
5 Year Return
+1,580.48%
10 Year Return
–
AUM
$1.33B
AUM Growth
+$1.33B
(+14%)
Cap. Flow
-$26.3M
Cap. Flow
% of AUM
-1.97%
Top 10 Holdings %
Top 10 Hldgs %
74.55%
Holding
40
New
3
Increased
4
Reduced
7
Closed
9
Top Buys
| 1 |
Oric Pharmaceuticals
ORIC
|
$34.7M |
| 2 |
JBIO
Jade Biosciences, Inc. Common Stock
JBIO
|
$32.2M |
| 3 |
CytomX Therapeutics
CTMX
|
$31.7M |
| 4 |
Savara
SVRA
|
$12.8M |
| 5 |
SEPN
Septerna, Inc. Common Stock
SEPN
|
$5.71M |
Top Sells
| 1 |
Praxis Precision Medicines
PRAX
|
$37.5M |
| 2 |
CBIO
Crescent Biopharma, Inc. Common Stock
CBIO
|
$26M |
| 3 |
Cidara Therapeutics
CDTX
|
$20.1M |
| 4 |
Pharvaris
PHVS
|
$18.7M |
| 5 |
Dianthus Therapeutics
DNTH
|
$13.9M |
Sector Composition
| 1 | Healthcare | 99.4% |
| 2 | Financials | 0.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Apogee Therapeutics
APGE
$2.17B
| $369M | 27.64% | 8,493,321 | – | – |
|
2
Ocular Therapeutix
OCUL
$2.12B
| $118M | 8.88% | 12,762,462 | – | – |
|
|
MTSR
3
Metsera, Inc. Common Stock
MTSR
$3.71B
| $107M | 8% | 3,750,662 | – | – |
|
4
Enliven Therapeutics
ELVN
$1.2B
| $80.8M | 6.05% | 4,026,331 | – | – |
|
5
KalVista Pharmaceuticals
KALV
$678M
| $76.1M | 5.7% | 6,728,985 +25,000 | +0.4% | +$283K |
|
|
6
Oric Pharmaceuticals
ORIC
$994M
| $67M | 5.02% | 6,596,885 +3,414,358 | +107% | +$34.7M |
|
7
Viridian Therapeutics
VRDN
$1.5B
| $54.3M | 4.07% | 3,882,709 | – | – |
|
|
ORKA
8
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $46.5M | 3.48% | 4,148,428 | – | – |
|
9
Spyre Therapeutics
SYRE
$996M
| $40.2M | 3.01% | 2,685,448 | – | – |
|
|
10
Pharvaris
PHVS
$1.39B
| $36M | 2.7% | 2,047,620 -1,065,100 | -34% | -$18.7M |
|
11
Cogent Biosciences
COGT
$1.69B
| $34.1M | 2.56% | 4,755,411 -929,000 | -16% | -$6.67M |
|
|
JBIO
12
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $32.2M | 2.41% | +3,220,364 | New | +$32.2M |
|
|
13
CytomX Therapeutics
CTMX
$336M
| $31.7M | 2.38% | +13,969,882 | New | +$31.7M |
|
|
14
Cidara Therapeutics
CDTX
$1.66B
| $31.1M | 2.33% | 639,088 -412,430 | -39% | -$20.1M |
|
|
UPB
15
Upstream Bio, Inc. Common Stock
UPB
$923M
| $25.2M | 1.89% | 2,295,319 | – | – |
|
16
Erasca
ERAS
$445M
| $22.7M | 1.7% | 17,857,083 +1,640,867 | +10% | +$2.08M |
|
|
CBIO
17
Crescent Biopharma, Inc. Common Stock
CBIO
$200M
| $22.4M | 1.68% | 1,387,864 -1,612,136 | -54% | -$26M |
|
18
Dyne Therapeutics
DYN
$1.92B
| $20.7M | 1.55% | 2,173,913 | – | – |
|
|
19
Savara
SVRA
$567M
| $20.3M | 1.52% | 8,884,263 +5,626,624 | +173% | +$12.8M |
|
|
20
Dianthus Therapeutics
DNTH
$759M
| $18.6M | 1.4% | 1,000,000 -744,373 | -43% | -$13.9M |
|
21
enGene Holdings
ENGN
$236M
| $18.4M | 1.38% | 5,046,414 | – | – |
|
22
Astria Therapeutics
ATXS
$349M
| $13.2M | 0.99% | 2,457,348 | – | – |
|
23
Cullinan Oncology
CGEM
$445M
| $10.4M | 0.78% | 1,379,965 | – | – |
|
|
ABVX
24
Abivax
ABVX
$6.12B
| $10.3M | 0.77% | 1,345,780 | – | – |
|
|
PCSC
25
Perceptive Capital Solutions Corp Class A Ordinary Shares
PCSC
$117M
| $7.97M | 0.6% | 750,000 | – | – |
|